Positive Results From Multi-Centre, Prospective Clinical Trial for Diagnosis of Basal Cell Carcinoma Using Michelson Diagnostics' VivoSight OCT Presented at AAD

ORPINGTON, England, March 21, 2014 /PRNewswire/ --

Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, today announces positive results from the successfully completed multi-centre, prospective clinical trial for the diagnosis of basal cell carcinoma using VivoSight OCT to be presented at the upcoming American Academy of Dermatology's 72nd Annual Meeting (AAD) in Denver, Colorado, 21-25 March 2014.

Papers by Professor Dr. med. Julia Welzel, Dr. med. Martina Ulrich discussing results from the clinical study will be presented in the AAD Conference Session F153 "Non-Invasive Imaging in Dermatology" on Tuesday, 25 March at 1.00pm.

The presented results support Michelson Diagnostics vision that its VivoSight OCT system has the potential to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect the skin, and in particular non-melanoma skin cancer.  For further information come and meet the team at the Michelson Diagnostics booth, number 2255 - http://show.aad.org/annual14/EC/forms/attendee/indexTab.aspx

The AAD Annual Meeting is the largest dermatology meeting in the world, with approximately 20,000 delegates expected from more than 90 countries.  The AAD supports the highest-quality patient care by developing and presenting information that enhances continuing education in dermatology.  AAD meetings offer the latest on the diagnosis, prevention, and treatment of dermatologic disease from the foremost experts in the field.

All abstracts and details on timings can be accessed through the AAD website: http://www.aad.org/meetings/2014-annual-meeting.

The title, timing and location of the poster presentations are as follows:

    Abstract         F153

    Title:           Non-Invasive Imaging in Dermatology
                     Orit Markowitz, MD, FAAD; Robert Bard, MD; Theresa Cao, DO;
                     Gerald Messer; Daniel M. Siegel, MD, MS, FAAD ; Dan Sperling,
    Authors:         MD; Martina Ulrich, MD; Julia Welzel, MD
                     This forum will address the utility of some of the most
                     recent dermatologic non-invasive imaging devices including
                     optical coherence tomography, the new handheld confocal
                     microscope, 3-D high resolution ultrasound, MRI as well as
                     MRI/US fusion. The attendee will be able to recognize basic
                     images with these devices, how they differ and understand
                     what role each plays in daily practice as well as in basic
                     dermatologic research. The most recent imaging advances
                     ranging from measuring in transit melanoma metastases,
                     visualization of field cancerization, monitoring non-invasive
                     treatment of skin cancer and even diagnosis of onychomycosis
    Session Info:    will be discussed.
    Day/Date:        Tuesday 25 March 2014
    Session Time:    1pm - 3pm Eastern Time
    Location :       Room 705/707

For  further  information

Notes  to  editors

About  Michelson  Diagnostics  and  the  VivoSight  System

Michelson Diagnostics has developed a world-leading, patented, medical imaging technology, known as multi-beam Optical Coherence Tomography ('OCT'), that uses an advanced laser scanner to 'see' into tissue with unprecedented image resolution and quality of image.  Multi-beam OCT has many potential clinical applications, but we are currently focusing on dermatology.

Our vision is for our VivoSight OCT system to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect cutaneous and epithelial linings of the body.  We currently generate revenues from our first commercial application of VivoSight, which is in the diagnosis of non-melanoma skin cancer (NMSC).

VivoSight has regulatory clearance in Europe, USA and Australia, for use by trained clinicians in their assessment of the patient's medical condition.  We have launched VivoSight in Germany where the VivoSight scan is reimbursed for patients with private healthcare insurance.

The Company, based in Orpington, Kent, was founded in 2006 and has 18 employees.  It has sales offices in Germany and USA.  It has been supported through funding from a syndicate of Venture Capital, corporate and private investors including Octopus, Catapult Ventures and Angel Investors.  

For more information about Michael Diagnostics, see http://www.michelsondiagnostics.com.

Michelson Diagnostics
Tel: +44(0)20-8308-1695
Jon Holmes, Chief Executive Officer    

FTI Consulting
Tel: +44(0)20-7831-3113
Simon Conway / Mo Noonan / Victoria Foster Mitchell

SOURCE Michelson Diagnostics